Fresenius SE & Co KGaA - Company Profile
Powered by 
All the sales intelligence you need on Fresenius SE & Co KGaA in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Fresenius SE & Co KGaA fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Fresenius SE & Co KGaA.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Fresenius SE & Co KGaA (Fresenius) is a global healthcare company that offers products and services for dialysis, hospitals, and outpatient treatment. It provides various dialysis services through its own clinics and markets products to other dialysis service providers. The company's major products and services include machines for hemodialysis, acute dialysis and peritoneal dialysis; solutions for infusion therapy; dialysis care services; liver support therapy services; and provision projects and services for hospitals and other health care facilities. It also operates and manages acute care and post-acute care hospitals in Germany through Helios Kliniken Group. Fresenius conducts operations in Europe, Asia-Pacific, Africa and the Americas. Fresenius is headquartered in Bad Homburg, Hessen, Germany.
Headquarters
Germany
Address
Else-Kroener-Str. 1, Bad Homburg, Hessen, 61352
Website
www.fresenius.com
Telephone
49 6172 6080
No of Employees
177,783
Industry
Medical Equipment
Ticker Symbol & Exchange
FRE (ETR)
Revenue (2024)
$25.8B
4.2%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
168.4%
(2024 vs 2023)
Market Cap*
$27.8B
Net Profit Margin (2024)
XYZ
157.2%
(2024 vs 2023)
* As of and is in US$
Fresenius SE & Co KGaA premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Fresenius Kabi: | End-Stage Renal Disease-Related Treatments | RoActemra |
| Infusion Therapy: | End-Stage Renal Disease-Related Laboratory Testing Services | Granuflo |
| I.V. Drugs | Acute Dialysis Services | Naturalyte |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Financing Agreements | In May, the company and SAP invested in Avelios Medical, a developer of a cloud-native hospital information system. |
| 2026 | Contracts/Agreements | In February, Fresenius Kabi entered into an agreement with Phlow Corp to establish a end-to-end supply chain for Epinephrine Injection. |
| 2026 | Contracts/Agreements | In January, the company entered into an agreement with TQ Therapeutics, to support the scalable and efficient manufacturing of cell and gene therapies. |
Competitor Comparison
| Key Parameters | Fresenius SE & Co KGaA | Nestle SA | Pfizer Inc | Amgen Inc | Danone SA |
|---|---|---|---|---|---|
| Headquarters | Germany | Switzerland | United States of America | United States of America | France |
| City | Bad Homburg | Vevey | New York City | Thousand Oaks | Paris |
| State/Province | Hessen | Waadt | New York | California | Ile-de-France |
| No. of Employees | 177,783 | 271,000 | 75,000 | 31,500 | 88,670 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Wolfgang Kirsch | Chairman | Executive Board | 2025 | 71 |
| Michael Sen | Chief Executive Officer | Senior Management | 2023 | 60 |
| Sara Hennicken | Chief Financial Officer | Senior Management | 2022 | 46 |
| Pierluigi Antonelli | Chief Executive Officer - Fresenius Kabi | Senior Management | 2023 | 60 |
| Michael Moser | Head - Legal, Compliance, Risk Management, ESG, Human Resources, and Fresenius Vamed | Senior Management | 2023 | 50 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer